Overview

Bioequivalence Study of 200 mg Lamotrigine Tablet Under Non-Fasting Conditions

Status:
Completed
Trial end date:
2002-02-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the rate and extent of absorption of lamotrigine 200 mg tablets (test) versus Lamictal® (reference) administered as 1 x 200 mg tablet under fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Pharmaceuticals USA
Treatments:
Anticonvulsants
Lamotrigine